

134. Synthesis and Monoamine Oxidase Inhibitory Activity of 3-Substituted 5*H*-Indeno[1,2-*c*]pyridazines

by Silvia Kneubühler^{a)}, Vincenzo Carta^{b)}, Cosimo Altomare^{b)}, Angelo Carotti^{b)}*, and Bernard Testa^{a)}*

^{a)} Institut de chimie thérapeutique, Ecole de Pharmacie, Université de Lausanne, CH-1015 Lausanne

^{b)} Dipartimento Farmacochimico, Università degli Studi di Bari, Via Orabona 4, I-70126 Bari

(2. IV. 93)

The one-pot synthesis of nine 5*H*-indeno[1,2-*c*]pyridazines is described. These compounds are shown to be potent, reversible inhibitors of monoamine oxidase B (MAO-B) with little or no effect on monoamine oxidase A (MAO-A). Qualitative structure-activity relations indicate that the MAO-B inhibitory activity is strongly influenced by electronic and bulk properties of substituents.

1. Introduction. – Monoamine oxidase (MAO, *EC* 1.4.3.4) exists in two forms, MAO-A and MAO-B, which differ by their primary structure, substrate specificity, and sensitivity to inhibitors [1–3].

Clinical results have suggested that MAO-A inhibitors could be effective for treating serotonin (5-HT) and noradrenaline (NA) deficits observed in depressive illnesses, whereas MAO-B inhibitors, when combined with the dopamine (DA) precursor L-DOPA, could be useful in alleviating the debilitating symptoms of *Parkinson's* disease [4–6].


Aryl-oxadiazine and aryl-oxadiazole derivatives have recently been described as selective and competitive MAO inhibitors [7] [8], an activity probably linked in part to the endocyclic 'hydrazine' functionality (=N–N=) they feature. On our side, we have been interested in the convenient synthesis and properties of indeno[1,2-*c*]pyridazine derivatives [9] which also contain the endocyclic hydrazine functionality.

Here, we describe the one-pot synthesis of some 3-substituted 5*H*-indeno[1,2-*c*]pyridazin-5-ones and analogs and report their MAO-A and MAO-B inhibitory activities.

2. Results. – *Chemistry.* Compounds 2–6 were prepared according to the reaction pathway shown in the *Scheme*. Intermediate aldol adducts **2c**, **e**, **g** [10], indeno-pyridazinones **3a** [11], **3b** [12], and **3c** [13] were previously synthesized by others through different procedures, as reported in the patent literature. Here, we used an efficient one-pot procedure to prepare the 5*H*-indeno[1,2-*c*]pyridazin-5-ones **3a**, **c**, **e**, **f** from ninhydrin and the corresponding ketones **1** (or acetaldehyde **1a**) as reported in a preliminary communication [9].

As expected, two isomeric compounds, namely **2d** and 2-hydroxy-2-(2-oxo-3-phenylpropyl)indane-1,3-dione were obtained from benzyl methyl ketone **1d** and separated by column chromatography on silica gel. Reductive transformation of CO at C(5) was performed on compound **3c** through *Grignard* addition of MeMgBr leading to **6** and

Scheme



through the *Caglioti* reaction [14] on **3c** leading to **5**. The yields and properties of the compounds are reported in *Table 1*.

MAO Inhibition. Our method, mainly based on that reported by *Weissbach et al.* [22] was validated by measuring the inhibitory activity of harman. The results obtained for MAO-A and MAO-B (IC_{50} 0.6 μM and 120 μM , respectively) compare very well with the literature data (IC_{50} 0.5 μM and 80 μM , respectively) [15].

Preliminary tests having shown the inhibitory activity of some of the investigated compounds, detailed studies were conducted. It was first established that the mechanism of inhibition is of a competitive type (*Fig. 1*) [16] [17], and, in contrast to other competitive inhibitors (*e.g.*, moclobemide, [2]), no time dependence was seen (data not shown).

Because the inhibition is of a competitive type, K_i values could be determined and are reported in *Table 2*. The MAO-B inhibitory activities range from nil to high (compound **3f**), whereas the MAO-A inhibitory activities are usually nil with only three compounds acting weakly.

3. Discussion. – Structural modifications of the indeno[1,2-*c*]pyridazine skeleton were carried out at C(3) and C(5) to obtain a preliminary evaluation of the physicochemical features mainly responsible for modulating MAO-B inhibitory activity. The property space at C(3) was thus explored for lipophilicity and bulk (compounds **3a–d**) and strong electronic effects (compounds **3e, f**), whereas the influence of conformational rigidity was

Table 1. Yields, Crystallization Solvents, Physicochemical and Spectral Data of Compounds **2**, **3**, **5**, and **6**

Compound	Yield [%]	Cryst. solv. (M.p. [°C])	IR ^{a)} (KBr [cm ⁻¹])	¹ H-NMR ^{b)}
2b	95	AcOEt/Hexane (142–143)	3320, 1750, 1710	1.77 (s, CH ₃ (3')); 3.08 (s, CH ₂ (1')); 6.04 (br. s, HO–C(2)); 7.40–7.80 (m, 4H–C(arom.))
2d	15	CHCl ₃ /Hexane (139–140)	3380, 1750, 1730, 1727	3.26 (s, CH ₂ (1')); 3.52 (br. s, HO–C(2)); 3.62 (s, CH ₂ (3')); 7.00–7.30 (m, 5 arom. H); 7.70–8.00 (m, 4 arom. H)
2g	90	CHCl ₃ /Hexane (174–175)	3380, 1750, 1710, 1680	2.45–2.80 (m, CH ₂ (3')); 3.00–3.30 (m, CH ₂ (4')); 3.60 (dd, <i>J</i> = 13, 5, H–C(2')); 6.83 (s, HO–C(2)); 7.13–7.70 (m, 4 arom. H); 7.90–8.20 (m, 4 arom. H)
3a	41	EtOH (164–165) ^{c)}	1720, 1390	7.55 (td, <i>J</i> = 7.5, 1.1, H–C(8)); 7.58 (d, <i>J</i> = 4.8, H–C(4)); 7.72 (td, <i>J</i> = 7.5, 1.1, H–C(7)); 7.78 (dt, <i>J</i> = 7.5, 1.1, H–C(9)); 8.15 (dt, <i>J</i> = 7.5, 1.1, H–C(6)); 9.24 (d, <i>J</i> = 4.8, H–C(3))
3b	76	EtOH (190–191) ^{d)}	1725, 1420	2.80 (s, CH ₃ –C(3)); 7.43 (s, H–C(4)); 7.54 (td, <i>J</i> = 7.2, 1.5, H–C(8)); 7.70 (td, <i>J</i> = 7.2, 1.5, H–C(7)); 7.81 (dt, <i>J</i> = 7.2, 1.5, H–C(9)); 8.14 (dt, <i>J</i> = 7.2, 1.5, H–C(6))
3c	49	EtOH (218–219) ^{e)}	1720, 1410	7.49–7.59 (m, 4H–C(3'–5',8)); 7.73 (td, <i>J</i> = 7.5, 1.1, H–C(7)); 7.84 (dt, <i>J</i> = 7.5, 1.1, H–C(9)); 7.98 (s, H–C(4)); 8.08–8.14 (m, 2H–C(2',6')); 8.17 (dt, <i>J</i> = 7.5, 1.1, H–C(6))
3d	90	EtOH (167–168 (dec.))	1725, 1415	4.20 (s, CH ₂ –C(3)); 7.30 (s, 5 arom. H); 7.36 (s, H–C(4)); 7.40–7.80 (m, 3H–C(7–9)); 8.14 (dt, <i>J</i> = 8, 1.5, H–C(6))
3e	66	Dioxane/EtOH (219–220) ^{d)}	1725, 1420	3.87 (s, CH ₃ O–C(4')); 7.04 (dt, <i>J</i> = 9.1, 2.2, 2H–C(3',5')); 7.53 (td, <i>J</i> = 7.5, 1.0, H–C(8)); 7.72 (td, <i>J</i> = 7.5, 1.0, H–C(7)); 7.83 (dt, <i>J</i> = 7.5, 1.0, H–C(9)); 7.93 (s, H–C(4)); 8.09 (dt, <i>J</i> = 9.1, 2.2, 2H–C(2',6')); 8.15 (dt, <i>J</i> = 7.5, 1.0, H–C(6))
3f	70	THF (318–320 (dec.))	1720, 1515, 1415, 1340	7.49–7.54 (m, 2H–C(2',6')); 7.59 (td, <i>J</i> = 7.5, 1.1, H–C(8)); 7.74–7.86 (m, 2H–C(7,9)); 8.17 (dt, <i>J</i> = 7.5, 1.1, H–C(6)); 8.23 (s, H–C(4)); 8.26–8.31 (m, 2H–C(3',5'))
3g	70	EtOH (180 (dec.))	1715, 1390	2.96 (t, <i>J</i> = 7.2, CH ₂ (11)); 3.43 (t, <i>J</i> = 7.2, CH ₂ (12)); 7.23–7.28 (m, H–C(10)); 7.37–7.41 (m, 2H–C(8,9)); 7.50 (td, <i>J</i> = 7.5, 1.2, H–C(3)); 7.68 (td, <i>J</i> = 7.5, 1.2, H–C(2)); 7.78 (dt, <i>J</i> = 7.5, 1.2, H–C(4)); 8.11 (dt, <i>J</i> = 7.5, 1.2, H–C(1)); 8.48–8.53 (m, H–C(7))
5	20	EtOH (139–140)	1470, 1420	3.93 (m, CH ₂ (5)); 7.40–7.60 (m, 6H–C(3'–5', 7–9)); 7.89 (t, <i>J</i> = 1.1, H–C(4)); 8.06–8.12 (m, 2H–C(2',6')); 8.28–8.33 (m, H–C(6))
6	55	AcOEt (190–191)	3250, 1415	1.75 (s, CH ₃ –C(5)); 5.85 (s, HO–C(5)); 7.46–7.51 (m, 5H–C(7,8,3'–5')); 7.65–7.67 (m, H–C(9)); 8.03 (s, H–C(4)); 8.08–8.14 (m, 3H–C(6,2',6'))

^{a)} Only the most significant absorption bands are listed. ^{b)} Recorded in the following solvents, CDCl₃: **2d**, **3a**, **b**, **c**, **d**, **e**, **g**, and **5**; (D₆)DMSO: **2b**, **g**, and **6**; (D₈)THF: **3f**. ^{c)} [11]: 160–161°. ^{d)} [12]: 185–187°. ^{e)} [13]: 216°.





Fig. 1. Lineweaver-Burk (a), Dixon (b), and Cornish-Bowden (c) plots for compound 3a

Table 2. Inhibition of MAO-A and MAO-B by 5H-Indeno[1,2-c]pyridazines



Compound	X	R	MAO-B		MAO-A
			IC_{50} [μ M]	pK_I	Inhibition ^{a)}
3a	C=O	H	27.5 ± 5.1	4.87	50 % ^{b)}
3b	C=O	Me	74.4 ± 2.5	4.33	20 % ^{b)}
3c	C=O	Ph	21.0 ± 0.6	5.15	none ^{d)}
3d	C=O	PhCH ₂	30.6 ± 0.3	4.82	none ^{b)}
3e	C=O	4'-MeO-C ₆ H ₄	3.22 ± 0.04	5.86	none ^{c)}
3f	C=O	4'-NO ₂ -C ₆ H ₄	0.50 ± 0.02	6.57	none ^{d)}
3g			no inhibition ^{c)}		none ^{c)}
5	CH ₂	Ph	23.4 ± 2.4	5.04	31 % ^{c)}
6	C(CH ₃)OH	Ph	no inhibition ^{b)}		none ^{b)}

^{a)} % Inhibition at maximum solubility. ^{b)} 100 μ M. ^{c)} 50 μ M. ^{d)} 25 μ M. ^{e)} 5 μ M.

studied through the synthesis of compound **3g**. Position 5 instead was only partly explored through suitable reductions of the ketone group leading to compounds **5** and **6**.

Table 2 clearly shows that the tested compounds are active inhibitors of MAO-B, with little or no activity towards MAO-A. In fact, the most active compound (**3f**) has an inhibitory activity towards MAO-B that is comparable to that of some highly active MAO-B inhibitors reported by *Da Prada et al.* [2].




Fig. 2. Qualitative structure-activity relationships of indeno[1,2-c]pyridazines for inhibition of MAO-B, relative to compound **3a** (R = H)

Evaluation of the data in Table 2 allows to derive some preliminary structure-activity relations, as summarized in Fig. 2. Among the 5*H*-indeno[1,2-*c*]pyridazine-5-one derivatives **3a–g**, the more potent MAO-B inhibitors are those with a Ph ring at C(3) (compounds **3c**, **e**, **f**). The electron-withdrawing NO₂ group (**3f**) as well as the electron-donating MeO group (**3e**) on the Ph ring give rise to a significant increase in inhibition potency. In particular, the NO₂ substituent in *para*-position increases activity by a factor of *ca.* 40.

While the influence of substituents on the Ph ring deserves further investigations, the example of compound **3g** could suggest that MAO-B inhibitory activity may also depend on the dihedral angle between the Ph ring and the tricyclic system.

Reduction of the C(5)=O group to a CH₂ yielded compound **5** which showed a MAO-B inhibition comparable to that of compound **3c**. This suggests that the presence of C=O in position 5 is not a critical requisite for MAO-B inhibition. Interestingly, the loss of C=O in position 5 produces a measurable IMAO-A activity (compared to **3c**).

S.K. and B.T. are indebted to the Swiss National Science Foundation for support. The valuable assistance of Ms. Ulrike Thull and the undergraduated student Marco Catto is gratefully acknowledged. The Italian authors are indebted to MURST (Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Rome) for financial support.

Experimental Part

General. Ninhydrin, acetaldehyde **1a**, and ketones **1b–g** were commercial products from Aldrich Chem. Co.

The following products were obtained from commercial sources and used without further purification: Na₂HPO₄, KCl, KH₂PO₄, DMSO, and sucrose (Fluka, CH–Buchs), kynuramine and clorgyline (Sigma Chemical Co., St. Louis, USA), (–)-deprenyl (RBI, Natick, USA), and harman (Aldrich Chemie, D–Steinheim).

M.p.: in an open capillary with a Mark II electrothermal apparatus, uncorrected. Column chromatography: on silica gel 60 (70–230 mesh, Merck). IR Spectra: as KBr pellets on a Perkin-Elmer 283 spectrophotometer. ¹H-NMR Spectra: at 200 MHz on a Varian XL-200 instrument; chemical shifts in δ values, downfield from TMS used as internal standard; exchange with D₂O was used to identify OH protons. Elemental analyses were carried out by G. Di Pinto on a Carlo Erba 1106 analyzer, and the results for C, H, N were within $\pm 0.40\%$ of the theoretical values.

3-Phenyl-5*H*-indeno[1,2-*c*]pyridazine-5-one (3c), 3-(4-Methoxyphenyl)-5*H*-indeno[1,2-*c*]pyridazine-5-one (3e), and 3-(4-Nitrophenyl)-5*H*-indeno[1,2-*c*]pyridazine-5-one (3f). One-Pot Procedure. A soln. of ninhydrin (1.78 g, 10 mmol) and 10 mmol of the appropriate methyl ketone (**1c**, **e**, **f**) in 20 ml of glacial AcOH was heated to reflux over a period of 3–4 h. Upon cooling to r.t., the mixture was diluted with 60 ml of MeCN and added with hydrazine hydrate 98% (0.74 ml, 15 mmol) under magnetic stirring. After 1–2 h, the yellow solid so formed was collected by filtration and recrystallized.

5*H*-Indeno[1,2-*c*]pyridazin-5-one (3a). Compound **3a** was obtained as above with the following slight modifications: a soln. of ninhydrin (1.78 g, 10 mmol) and acetaldehyde (0.79 ml, 14 mmol) in 20 ml of glacial AcOH was heated in a suitably protected sealed tube at 125° for 5 h. The mixture, upon dilution with 200 ml of MeCN, was reacted with hydrazine hydrate 98% (0.74 ml, 15 mmol) for 1 h at r.t., under magnetic stirring. The mixture was evaporated to dryness and the residue chromatographed on a silica-gel column with hexane/AcOEt to give pure **3a**.

2-Hydroxy-2-(2-oxopropyl)indane-1,3-dione (2b), 2-Hydroxy-2-(2-oxo-3-phenylpropyl)indane-1,3-dione (2d), and 2-Hydroxy-2-(1,2,3,4-tetrahydro-1-oxonaphthalen-2-yl)indane-1,3-dione (2g). A soln. of ninhydrin (1.78 g, 10 mmol) and ketone **1b**, **d**, **g** (50, 10, 10 mmol, resp.) in 20 ml of AcOH was heated to reflux over 1 h (5 h for **1g**). The mixture was evaporated to dryness to give a solid residue which was recrystallized to yield pure **2b** and **2g** or chromatographed on silica-gel column with hexane/AcOEt/i-PrOH 75:20:5 to yield **2d** (*R_f* 0.36) and the isomeric 2-hydroxy-2-(2-oxo-3-phenylpropyl)indane-1,3-dione (*R_f* 0.43; 65% yield; m.p. 140–141°, from acetone/hexane).

3-Methyl-5*H*-indeno[1,2-*c*]pyridazin-5-one (3b), 3-Benzyl-5*H*-indeno[1,2-*c*]pyridazin-5-one (3d), and Benzof[1,3-*h*]-13*H*-indeno[1,2-*c*]cinnolin-13-one (3g). CF₃COOH (0.1 ml) was added to a soln. of hydrazine hydrate 98%

(0.74 ml, 10 mmol) and **2b, d, g** in anh. EtOH (100–200 ml) under magnetic stirring. The yellow solid which was formed within 1 h was collected by filtration and recrystallized.

3-Phenyl-5H-indeno[1,2-c]pyridazin-5-one Tosylhydrazone (4). A soln. of tosylhydrazine (3.72 g, 20 mmol) and **3c** (2.58 g, 10 mmol) in 100 ml of CHCl_3 was stirred at r.t. over 24 h. The resulting orange solid was collected and used without further purification for the subsequent reduction.

3-Phenyl-5H-indeno[1,2-c]pyridazine (5). A soln. of **4** (0.426 g, 1 mmol), $\text{TsOH} \cdot \text{H}_2\text{O}$ (40 mg, 0.21 mmol), and NaCNBH_3 (0.251 g, 4 mmol) in 40 ml of EtOH was heated at reflux for 1 h. The solid residue was filtered off, and the soln., evaporated to dryness and chromatographed on silica-gel column with CHCl_3 /hexane 90:10, afforded the title compound.

5-Hydroxy-5-methyl-3-phenyl-5H-indeno[1,2-c]pyridazine (6). 3M soln. (2 ml) of CH_3MgCl in THF was added dropwise under N_2 to an ice-cooled, stirred soln. of **3c** (2 mmol) in THF (20 ml). After 10 min, the mixture was allowed to warm to r.t., stirred for 1 h, and added with 10 ml of a 0.35M aq. soln. of KHSO_4 . The resulting mixture was extracted with CHCl_3 , and the org. layers washed with brine and H_2O , dried (Na_2SO_4), and evaporated to dryness. The residue was chromatographed on silica gel with hexane/AcOEt 60:40 to yield pure **5**.

Preparation of Rat Brain Mitochondria. Rat brain mitochondria were isolated according to the method of Clark and Nicklas [18] modified by Walther *et al.* [19]. For further details, see Thull *et al.* [20].

The protein content of the washed mitochondrial fraction was determined according to the procedure of Lowry *et al.* [21] with bovine serum albumin as a standard.

MAO Inhibition. The method of Weissbach *et al.* [22] was modified in order to measure inhibitor activities [23]. Incubations were carried out at pH 7.4 ($\text{Na}_2\text{HPO}_4/\text{KH}_2\text{PO}_4$ isotonized with KCl) at 37° . The mitochondrial suspension was set to a final protein concentration of 1.0 mg/ml. The mitochondria were preincubated at 37° for 5 min with clorgyline (250 nM) or (–)-deprenyl (250 nM) to test MAO-B or MAO-A activity, respectively. The inhibitor under study was solubilized in DMSO, added to give a final DMSO concentration of 5% (v/v), and further incubated for 5 min. Preliminary experiments had verified that DMSO at this concentration does not affect MAO activity. The nonselective substrate kynuramine is deaminated by MAO to an aldehyde that spontaneously cyclizes to quinolin-4-ol. Formation of the latter was monitored continuously at 314 nm using a Kontron Uvikon 941 spectrophotometer.

In preliminary experiments, IC_{50} values were estimated. Incubations were then carried out with four different substrate concentrations ($0.5 K_M$, $1 K_M$, $2 K_M$, $4 K_M$; $K_M = 90 \mu\text{M}$ for MAO-A, $60 \mu\text{M}$ for MAO-B) without inhibitor or with an inhibitor concentration of $0.5 IC_{50}$, $1 IC_{50}$, or $2 IC_{50}$, respectively. K_1 values were determined by Lineweaver-Burk and Dixon plots. IC_{50} values were calculated from a hyperbolic equation described in [20]. Time-dependence was tested by preincubation times of 5 and 15 min at 37° for one inhibitor concentration.

A second method used was a fluorimetric assay described by Snyder and Hendley [24] with a peroxidase substrate recommended by Zaitsev and Ohkura [25] and modified in our laboratory to monitor the reaction continuously. Incubations were carried out at pH 8.0 ($\text{Na}_2\text{HPO}_4/\text{KH}_2\text{PO}_4$ isotonized with KCl) at 37° . The mitochondrial suspension was set to a final protein concentration of 0.1 mg/ml. The mitochondria were preincubated at 37° for 5 min with horseradish peroxidase (HRP, 2 U/ml) and either clorgyline (250 nM) or (–)-deprenyl (250 nM). The inhibitor under study was solubilized in DMSO, added to give a final DMSO concentration of 5% (v/v), and further incubated for 5 min. Preliminary experiments had verified that DMSO at this concentration does not affect MAO nor HRP activities. Then the fluorogenic substrate hydroxyphenylpropionic acid (HPPA, 10^{-4} M) and finally the nonselective MAO substrate decylamine – at a concentration of K_M ($14 \mu\text{M}$ for MAO-A, $6 \mu\text{M}$ for MAO-B) – were added and the formation of the fluorescent HPPA-dimer followed at the wavelengths λ_{ex} 320 nm, λ_{em} 404 nm.

Calibration was carried out under the same conditions, H_2O_2 being added instead of decylamine at concentrations ranging from 0.025 to $0.25 \mu\text{M}$. For each inhibitor concentration a separate calibration was necessary.

The UV and fluorimetric methods led to comparable IC_{50} values; in Table 2, IC_{50} values coming from the former assay are reported.

REFERENCES

- [1] E. Kyburz, *Drug News Persp.* **1990**, 3, 592.
- [2] M. Da Prada, R. Kettler, H. H. Keller, A. M. Cesura, J. G. Richards, J. Saura Marti, D. Muggli-Maniglio, P.-C. Wyss, E. Kyburz, R. Imhof, *J. Neural Transm.* **1990**, [Suppl.] 29, 279.
- [3] M. Strolin-Benedetti, P. Dostert, in 'Advances in Drug Research', Ed. B. Testa, Academic Press, London, 1992, Vol. 23, p. 65.
- [4] D. L. Murphy, T. Sunderland, N. A. Garick, C. S. Aulakh, R. M. Cohen, in 'Clinical Pharmacology in Psychiatry', Eds. S. G. Dhal, L. F. Gram, S. M. Paul, and W. Z. Potter, Springer-Verlag, Berlin, 1987, p. 135.
- [5] M. B. H. Youdim, J. P. M. Finberg, K. F. Tipton, in 'Catecholamines I', Eds. U. Trendelenburg and N. Weiner, Springer-Verlag, Berlin, 1988, p. 119.
- [6] J. Knoll, *Adv. Neurol.* **1986**, 45, 107.
- [7] F. Mazouz, L. Lebreton, R. Milcent, C. Burstein, *Eur. J. Med. Chem.* **1988**, 23, 441.
- [8] F. Mazouz, L. Lebreton, R. Milcent, C. Burstein, *Eur. J. Med. Chem.* **1990**, 25, 659.
- [9] A. Carotti, V. Carta, F. Campagna, C. Altomare, G. Casini, *Farmaco* **1993**, 48, 137.
- [10] J. P. Poupelin, G. Narcisse, *Fr. Demande* 2, 382,424 (CA : **1979**, 91, 56700z).
- [11] G. Cignarella, M. Loriga, G. A. Pinna, M. A. Pirisi, P. Schiatti, D. Selva, *Farmaco* **1982**, 37, 133.
- [12] K. Hagiwara, T. Hidaka, *Jpn. Kokai Tokkio Koho*, JP 03161478 (CA : **1991**, 115, 208008j).
- [13] S. R. Ramadas, D. V. Ramana, P. V. Padmanabhan, *Indian IN* 152, 484 (CA : **1985**, 102, 95684n); P. V. Padmanabhan, K. J. Jagannadha, D. V. Ramana, S. R. Ramadas, *Heterocycles* **1981**, 16, 1.
- [14] L. Caglioti, *Tetrahedron* **1966**, 22, 487.
- [15] V. Glover, J. Liebowitz, I. Armando, M. Sandler, *J. Neural Transm.* **1982**, 54, 209.
- [16] P. C. Engel, in 'The Chemistry of Enzyme Action', Ed. M. I. Page, Elsevier, Amsterdam, 1984, p. 73.
- [17] A. Cornish-Bowden, *Biochem. J.* **1974**, 137, 143.
- [18] J. B. Clark, W. J. Nicklas, *J. Biol. Chem.* **1970**, 245, 4724.
- [19] B. Walther, J. F. Ghersi-Egea, Z. Jayyosi, A. Minn, G. Siest, *Neurosci. Lett.* **1987**, 76, 58.
- [20] U. Thull, S. Kneubühler, B. Testa, M. F. M. Borges, M. M. M. Pinto, *Pharmac. Res.* **1993**, in press.
- [21] O. H. Lowry, N. J. Rosebrough, L. Farr, R. J. Randell, *J. Biol. Chem.* **1951**, 193, 265.
- [22] H. Weissbach, T. E. Smith, J. W. Daly, B. Witkop, S. Udenfriend, *J. Biol. Chem.* **1960**, 235, 1160.
- [23] K. F. Tipton, in 'Techniques in the Life Sciences, Protein and Enzyme Biochemistry', Ed. K. F. Tipton, Elsevier, Dublin, 1985, BS 113, BI/II Suppl., p. 1.
- [24] S. H. Snyder, E. H. Hendley, *J. Pharmacol. Exp. Ther.* **1968**, 163, 368.
- [25] K. Zaitsu, Y. Ohkura, *Anal. Biochem.* **1980**, 109, 109.